Scarica l'app Stockscreener
0.00
100.00%
-31.49
Dopo l'orario di chiusura:
31.48
31.48
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$31.49
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$3.85B
Reddito:
$596.96M
Utile/perdita netta:
$221.32M
Rapporto P/E:
0.00
EPS:
1.7397
Flusso di cassa netto:
$208.13M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
0.00 | 3.85B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals, Inc. Revenue Breakdown – LS:A0LCUL - TradingView
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CPRX|Catalyst Pharmaceuticals Inc|Price:31.490| - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Cash Flow - TradingKey
TradingKey - TradingKey
Catalyst Pharmaceuticals | 8-K/A: Current report (Amendment) - Moomoo
Catalyst Pharmaceuticals stock steadies as investors weigh latest earnings momentum - AD HOC NEWS
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple - TechStock²
Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent - TechStock²
Catalyst Pharmaceuticals CLO Brian Elsbernd Sells 242,501 Shares Amid Angelini Pharma Acquisition Completion - Kalkine Media
Catalyst Pharmaceuticals (CPRX) director’s RSUs and options cashed out in merger - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
Angelini deal converts CATALYST PHARMACEUTICALS (NASDAQ: CPRX) officer equity to cash - Stock Titan
Catalyst Pharmaceuticals (CPRX) CCO exits equity in Angelini merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CEO equity converted to cash at $31.50 merger price - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO equity awards canceled for cash in Angelini merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CFO equity cancelled for cash in acquisition - Stock Titan
Catalyst Pharmaceuticals (CPRX) director’s RSUs and options cancelled in merger - Stock Titan
CATALYST PHARMACEUTICALS, INC. SEC Filing (Jul 17, 2026) - Stock Titan
Catalyst Pharmaceuticals, Inc. Files 8-K: Merger Agreement Details, Corporate Information & XBRL Data (2026) - Minichart
Angelini Pharma completes $4.1 billion Catalyst acquisition By Investing.com - Investing.com Australia
Italy’s Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - 1470 & 100.3 WMBD
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst - Reuters
CATALYST PHARMACEUTICALS, INC. SEC Filing (Jul 15, 2026) - Stock Titan
Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Angelini Pharma completes $4.1 billion Catalyst acquisition - Investing.com
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals - NTB Kommunikasjon
Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA - TechStock²
Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Growth and a High-Quality Technical Breakout Setup - ChartMill
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 1000 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Composite 1500 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P TMI Index - marketscreener.com
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Global BMI Index - marketscreener.com
Angelini Pharma S.p.a. completed the acquisition of Catalyst Pharmaceuticals, Inc. from a group of shareholders. - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board - Sahm
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Catalyst Pharmaceuticals (CPRX) Holds Steady Near Support as Consolidation PersistsBearish Pattern Stocks - Bölüm Sonu Canavarı
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth - ChartMill
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance
Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion - Pluang
Solaris Energy Infrastructure Set to Join S&P SmallCap 600 - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Proxy filing Summary - Quartr
Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary - Quartr
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst Pharma Shareholders Approve Angelini Merger Agreement - TipRanks
Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal - Stock Titan
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):